Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Bladder cancer is the 8th most common cancer in the UF Health Cancer Center catchment area and the 7th most common cancer presenting to UFHealth. Most newly diagnosed cases are stage I bladder cancer, which is defined by having no deep muscle invasion and no evidence of disease beyond the bladder. The current use in BCG (Bacillus Calmette-Guerin) refractory disease and the ongoing evaluation in BCG naïve high-risk disease support evaluation of intravesical gemcitabine and docetaxel in decreasing disease recurrence in intermediate risk stage I bladder cancer. This study will investigate the ef

Trial Details

NCT ID
NCT06488222
Phase
PHASE2
Sponsor
University of Florida
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • Docetaxel
  • Gemcitabine
Locations (sample)
  • Gainesville, Florida, United States|29.65163,-82.32483

Key Eligibility Criteria

  • Adults ≥ 18 years of age.
  • Low-grade (Ta) Intermediate risk urothelial carcinoma of the bladder (defined as recurrent low-grade Ta, solitary low-grade Ta \> 3 cm, multifocal …
  • ECOG Performance Status of 0-2.
  • No evidence of upper tract urothelial carcinoma based on CT, MRI, or retrograde pyelograms.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →